AlphaYou
Overview
8 funds hold it and 1 straight earnings beat.
Key stats
Sep 7- Open
- $257.96
- 52-wk high
- $267.47
- High
- $258.91
- 52-wk low
- $189.40
- Low
- $255.58
- Prev close
- $260.21
- Mkt cap
- $453.19B
- P/E
- 72.5x
- Volume
- 4.73M
- Fwd P/E
- 16.1x
- Beta
- 0.28
- Div yield
- 2.62%
- P/S
- 7.0x
- P/B
- 50.5x
- Profit margin
- +9.8%
- Op margin
- +40.0%
- ROE
- +62.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and 1 fin-fluencer is discussing it.
What funds are doing
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
$3.64 expected
Revenue
$16.76B expected
GAAP EPS was $2.03; adjusted EPS matches the analyst basis.
What the street expects next
EPS expected
$3.77 to $3.87
Revenue expected
18 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.78B | $16.62B | $15.00B | $16.99B |
| Cost of what it sold | $5.30B | $4.55B | $4.22B | $4.29B |
| Gross profit | $10.47B | $12.07B | $10.78B | $12.70B |
| What it spent | ||||
| Research and development | $2.32B | $2.58B | $2.47B | $2.34B |
| Sales and admin | $3.57B | $3.90B | $3.58B | $3.63B |
| Other operating costs | $2.68B | -$217.0M | — | $291.0M |
| Total operating expenses | $8.57B | $6.26B | $6.05B | $6.27B |
| What was left | ||||
| Operating profit | $1.90B | $5.81B | $4.73B | $6.43B |
| Interest on debt | $739.0M | $714.0M | $717.0M | $746.0M |
| Profit before tax | $714.0M | $2.67B | $1.04B | $4.28B |
| Tax | $526.0M | $853.0M | $342.0M | $662.0M |
| Net profit | $186.0M | $1.82B | $699.0M | $3.61B |
| EBITDA | $3.52B | $5.37B | $3.69B | $8.66B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
BullishSep 4AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
Leans bullishSep 4The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge
Leans bullishSep 4AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma
BullishSep 4AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance
Leans bullishSep 3AbbVie's Etentamig Delivers 74% Response Rate in Pivotal Cancer Trial
BullishSep 3AbbVie Touts Positive Data For Multiple Myeloma Drug
BullishSep 3ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
BullishSep 3
Macro
31 macro signals shaping ABBV right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results